摘要
目的:观察多西他赛联合奈达铂诱导方案治疗局部晚期头颈部鳞癌的近期疗效及不良反应。方法入选2014年1月到2015年12月我科收治的初治局部晚期头颈部鳞癌共52例。接受多西他赛75 mg/m2,d1,加奈达铂80 mg/m2,d1方案化疗,21 d一周期,2~4周期。每两个周期进行疗效评估和不良反应评估。结果52例患者均顺利完成2?4次诱导化疗。 CR患者8例(15?4%),PR患者34例(65?4%),SD患者6例,PD患者4例。不论是在鼻咽癌还是其他头颈鳞癌均取得了很好的疗效(CR+PR达到80?8%),同时不良反应相对轻微,尤其是恶心呕吐不良反应较其他联合顺铂方案明显减轻,提高了患者的化疗耐受力和依从性。结论多西他赛联合奈达铂诱导方案近期疗效显著,不良反应轻微。
Objective To explorer the efficacy and adverse reaction of docetaxal plus nedaplatin for the induction chemotherapy of local advanced head and neck squamous cell carcinoma( HNSCC)?Methods A total of 52 cases first treatment patients with local advanced head and neck squamous cell carcinoma were enrolled in Oncology Department of Hunan Province People′s Hospital from January 2014 to December 2015?The chemo?therapy regimen consisted of docetaxel(75 mg/m2,day 1),Nedaplatinevery(80 mg/m2,day 1),21 days for a period?All patients completed 2-4 cycles of chemotherapy?The efficacy and adverse effects of per two cycles were evaluated?Results All patients were successfully completed 2-4 times of induction chemotherapy?There were 8 cases patients(15?4%) showed complete response(CR),34 cases patients(65?4%) showed partial re?sponse(PR),6 cases patients(11?5%) showed stable disease(SD),4 cases patients(7?7%) showed disease progression(PD)?The response rate(CR+PR) was 80?8% no whether in nasopharyngeal carcinoma or other head and neck squamous cell carcinoma?At the same time,the adverse reactions were mild,especially the ad?verse reactions of nausea and vomiting were significantly reduced compared with other combined cisplatin regi?men,which improved the chemotherapy tolerance and compliance of patients?Conclusion Docetaxel plus neda?platin is with short period efficacious and well tolerated in the induction chemotherapy of local advanced head and neck squamous cell carcinoma,which deserve further clinical research.
出处
《中国综合临床》
2016年第12期-,共3页
Clinical Medicine of China
关键词
多西他赛
奈达铂
诱导化疗
头颈部鳞癌
鼻咽癌
Docetaxel
Nedaplatinevery
Induction-chemotherapy
Head and neck squamous cell carcinoma
Nasopharyngeal-carcinoma